sebacoyl dinalbuphine ester

Trade name: Naldebain

Small moleculeexperimental

Dinalbuphine sebacate (DNS), also known as nalbuphine sebacate or as sebacoyl dinalbuphine ester (SDE) and sold under the brand name Naldebain, is a non-controlled opioid analgesic which is used as a 7-day long-acting injection in the treatment of moderate to severe postoperative pain. — Wikipedia

Clinical trial activity

7 trials · 9 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
2
Phase 3
2
Phase 4
2

Earliest trial started Dec 1, 2012 (NCT02468128)

Timeline

2010s

  1. Jan 1, 2012

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • sebacoyl dinalbuphine ester
  • sebacoyl dinalbuphine ester

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06344169Phase 2/Phase 3 (Phase 3)Apr 15, 2024Dalin Tzu Chi General Hospital, Hualien Tzu Chi Hospital
NCT05842733Phase 2Jul 25, 2023Sinew Pharma Inc., Taipei Veteran General hospital
NCT05187520Phase 2Sep 1, 2022I-Shou University
NCT03854851Phase 4Mar 1, 2019China Medical University
NCT03713216Phase 4Jul 1, 2018Cathay General Hospital
NCT02446301Phase 1Jan 1, 2015Lumosa Therapeutics Co., Ltd.
NCT02468128Phase 2/Phase 3 (Phase 3)Dec 1, 2012Chang Gung University, Lumosa Therapeutics Co., Ltd.
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Lumosa Therapeutics Co., Ltd.For profit2222012
Cathay General HospitalAcademic/Hospital1112018
Chang Gung UniversityAcademic/Hospital1012012
China Medical UniversityAcademic/Hospital1112019
Dalin Tzu Chi General HospitalAcademic/Hospital1112024
Hualien Tzu Chi HospitalAcademic/Hospital1012024
I-Shou UniversityAcademic/Hospital1112022
Sinew Pharma Inc.For profit1112023
Taipei Veteran General hospitalGovernment1012023
9 organizations
Page 1 / 1